Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects

MARIE MARANINCHI; NADÈGE PADILLA; SOPHIE BÉLIARD; BRUNO BERTHET; JUAN-PATRICIO NOGUEIRA; JEANINE DUPONT-ROUSSEL; JULIEN MANCINI; AUDREY BÉGU-LE CORROLLER; NOÉMIE DUBOIS; RACHEL GRANGEOT; CATHERINE MATTEI; MARION MONCLAR; ANASTASIA CALABRESE; CAROLE GUÉRIN; CHARLES DESMARCHELIER; ALAIN NICOLAY; CHANGTING XIAO; PATRICK BOREL; GARY F. LEWIS; RENÉ VALÉRO

JOURNAL OF CLINICAL LIPIDOLOGY

ELSEVIER SCIENCE INC

Lugar: Amsterdam; Año: 2017

1933-2874

Background: Elevated apolipoprotein C-III (apoC-III) has been postulated to contribute to the atherogenic dyslipidemia seen in obesity and insulin-resistant states, mainly by impairing plasma triglyceride-rich lipoprotein (TRL) metabolism. Bariatric surgery is associated with improvements of several obesity-associated metabolic abnormalities, including a reduction in plasma triglycerides (TG) andan increase in plasma high density lipoprotein-cholesterol (HDL-C).Objectives: We investigated the specific effect of bariatric surgery on apoC-III concentrations in plasma, non HDL and HDL fractions in relation to lipid profile parameters evolution.Methods: A total of 132 obese subjects undergoing bariatric surgery: gastric bypass (n=61) or sleeve gastrectomy (n=71) were studied one month before surgery and 6 and 12 months after surgery.Results: Plasma apoC-III, non HDL-apoC-III and HDL-apoC-III concentrations were markedly reduced after surgery and strongly associated with reduction in plasma TG. This decrease was accompanied by a redistribution of apoC-III from TRL to HDL fractions. In multivariate analysis, plasma apoC-III was the strongest predictor of TG reduction after surgery and the increase of HDL-C was positively associated with plasma adiponectin and negatively with BMI.Conclusion: Marked reduction of apoC-III and changes in its distribution between TRL and HDL consistent with a better lipid profile are achieved in obese patients following bariatric surgery. These apoC-III beneficial modifications may have implications in dyslipidemia improvement and contribute to cardiovascular risk reduction after surgery.